Reproductive function involves an interaction of three regulatory levels: hypothalamus, pituitary, and gonad. The primary drive upon this system comes from hypothalamic gonadotropin-releasing hormone (GnRH) neurosecretory cells, which receive afferent inputs from other neurotransmitter systems in the central nervous system to result in the proper coordination of reproduction and the environment. Here, we hypothesized that the recreational drug (±)-3,4-methylenedioxymethamphetamine (MDMA; ‘ecstasy’), which acts through several of the neurotransmitter systems that affect GnRH neurons, suppresses the hypothalamic-pituitary-gonadal reproductive axis of male rats. Adult male Sprague-Dawley rats self-administered saline or MDMA either once (acute) or for 20 days (chronic) and were euthanized 7 days following the last administration. We quantified hypothalamic GnRH mRNA, serum luteinizing hormone concentrations, and serum testosterone levels as indices of hypothalamic, pituitary, and gonadal functions, respectively. The results indicate that the hypothalamic and gonadal levels of the hypothalamic-pituitary-gonadal axis are significantly altered by MDMA, with GnRH mRNA and serum testosterone levels suppressed in rats administered MDMA compared to saline. Furthermore, our finding that hypothalamic GnRH mRNA levels are suppressed in the context of low testosterone concentrations suggests that the central GnRH neurosecretory system may be a primary target of inhibitory regulation by MDMA usage.

Keywords:
Ecstasy (MDMA), Gonadotropin-releasing hormone, Testosterone, Endocrine disruption, Male reproduction
1.
Strote J, Lee JE, Wechsler H: Increasing MDMA use among college students: results of a national survey. J Adolesc Health 2002;30:64–72.
2.
Boyd C, McCabe S, d’Arcy H: Ecstasy use among college undergraduates: gender, race and sexual identity. J Subst Abuse Treat 2003;24:209–215.
3.
Kalechstein AD, De La Garza R 2nd, Mahoney JJ 3rd, Fantegrossi WE, Newton TF: MDMA use and neurocognition: a meta-analytic review. Psychopharmacology (Berl) 2007;189:531–537.
4.
Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K: Cognitive performance in recreational users of MDMA of ‘ecstasy’: evidence for memory deficits. J Psychopharmacol 1998;12:79–83.
5.
Verkes RJ, Gijsman HJ, Pieters MS, Schoemaker RC, de Visser S, Kuijpers M, Pennings EJ, de Bruin D, Van de Wijngaart G, Van Gerven JM, Cohen AF: Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology (Berl) 2001;153:196–202.
6.
Balogh B, Molnar E, Jakus R, Quate L, Olverman HJ, Kelly PA, Kantor S, Bagdy G: Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA. Psychopharmacology (Berl) 2004;173:296–309.
7.
Dafters RI, Biello SM: The effect of 3,4-methylenedioxymethamphetamine (‘ecstasy’) on serotonergic regulation of the mammalian circadian clock mechanism in rats: the role of dopamine and hyperthermia. Neurosci Lett 2003;350:117–121.
8.
Reveron ME, Maier EY, Duvauchelle CL: Experience-dependent changes in temperature and behavioral activity induced by MDMA. Physiol Behav 2006;89:358–363.
9.
Banks ML, Sprague JE, Kisor DF, Czoty PW, Nichols DE, Nader MA: Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. Drug Metab Dispos 2007;35:1840–1845.
10.
Green AR, Mechan AO, Elliott JM, O’Shea E, Colado MI: The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’). Pharmacol Rev 2003;55:463–508.
11.
Stone DM, Merchant KM, Hanson GR, Gibb JW: Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 1987;26:1677–1683.
12.
Schmidt CJ, Taylor VL: Depression of rat brain tryptophan hydroxylase following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 1987;36:4095–4102.
13.
Yamamoto BK, Spanos LJ: The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol 1988;148:195–203.
14.
Colado MI, O’Shea E, Granados R, Esteban B, Martín AB, Green AR: Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’) administration. Br J Pharmacol 1999;126:911–924.
15.
Bogen IL, Haug KH, Myhre O, Fonnum F: Short- and long-term effects of MDMA (‘ecstasy’) on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo. Neurochem Int 2003;43:393–400.
16.
Mlinar B, Mascalchi S, Morini R, Giachi F, Corradetti R: MDMA induces EPSP-spike potentiation in rat ventral hippocampus in vitro via serotonin and noradrenaline release and coactivation of 5-HT4 and beta1 receptors. Neuropsychopharmacology E-pub ahead of print. DOI 10.1038/sj.npp.1301512.
17.
Steele TD, Nichols DE, Yim GK: Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 1987;36:2297–2303.
18.
Johnson MP, Conarty PF, Nichols DE: [3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur J Pharmacol 1991;200:9–16.
19.
Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS: Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001;39:32–41.
20.
Fitzgerald JL, Reid JJ: Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices. Naunyn Schmiedebergs Arch Pharmacol 1993;347:313–323.
21.
Fischer HS, Zernig G, Schatz DS, Humpel C, Saria A: MDMA (‘ecstasy’) enhances basal acetylcholine release in brain slices of the rat striatum. Eur J Neurosci 2000;12:1385–1390.
22.
Acquas E, Marrocu P, Pisanu A, Cadoni C, Zernig G, Saria A, DiChiara G: Intravenous administration of ecstasy (3,4-methylenedioxymethamphetamine) enhances cortical and striatal acetylcholine release in vivo. Eur J Pharmacol 2001;418:207–211.
23.
Nair SG, Gudelsky GA: 3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat. Psychopharmacology (Berl) 2006;184:182–189.
24.
Bankson MG, Yamamoto BK: Serotonin-GABA interactions modulate MDMA-induced mesolimbic dopamine release. J Neurochem 2004;91:852–859.
25.
Drouva SV, Gallo RV: Further evidence for inhibition of episodic luteinizing hormone release in ovariectomized rats by stimulation of dopamine receptors. Endocrinology 1977;100:792–798.
26.
Vitale ML, de las Nieves Parisi M, Chiocchio SR, Tramezzani JH: Serotonin stimulates gonadotrophin release by acting directly on the median eminence. Acta Physiol Pharmacol Latinoam 1985;35:473–479.
27.
Gore AC, Terasawa E: Neural circuits regulating pulsatile luteinizing hormone release in the female guinea-pig: opioid, adrenergic and serotonergic interactions. J Neuroendocrinol 2001;13:239–248.
28.
Gore AC: GnRH: The Master Molecule of Reproduction. Norwell, Kluwer Academic Publishers, 2002.
29.
Schenk S, Gittings D, Johnstone M, Daniela E: Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats. Psychopharmacology (Berl) 2003;169:21–27.
30.
Vella S, Gussick J, Woller M, Waechter-Brulla D: Modification of cell perifusion for extended study of hormone release in the rat pituitary. Methods Cell Sci 2001;23:197–204.
31.
Maffucci JA, Walker DM, Ikegami A, Woller MJ, Gore AC: The NMDA receptor subunit NR2b: effects on LH release and GnRH gene expression in young and middle-aged female rats, with modulation by estradiol. Neuroendocrinology 2007, E-pub ahead of print. DOI 10.1159/000111136.
32.
Gore AC, Roberts JL, Gibson MJ: Mechanisms for the regulation of gonadotropin-releasing hormone gene expression in the developing mouse. Endocrinology 1999;140:2280–2287.
33.
Schirman-Hildesheim TD, Bar T, Ben-Aroya N, Koch Y: Differential gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acid expression patterns in different tissues of the female rat across the estrous cycle. Endocrinology 2005;146:3401–3408.
34.
Medhurst AD, Harrison DC, Read SJ, Campbell CA, Robbins MJ, Pangalos MN: The use of TaqMan RT-PCR assays for semiquantitative analysis of gene expression in CNS tissues and disease models. J Neurosci Methods 2000;98:9–20.
35.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C(T)] Method. Methods 2001;25:402–408.
36.
Peroutka SJ, Newman H, Harris H: Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988;1:273–277.
37.
Mas M, Farre M, De La Torre R, Roset PN, Ortuno J, Segura J, Cami J: Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999;290:136–145.
38.
Solowij N, Hall W, Lee N: Recreational MDMA use in Sydney: a profile of ‘ecstasy’ users and their experiences with the drug. Br J Addict 1992;87:1161–1172.
39.
El Majdoubi M, Ramaswamy S, Sahu A, Plant TM: Effects of orchidectomy on levels of the mRNAs encoding gonadotropin-releasing hormone and other hypothalamic peptides in the adult male rhesus monkey (Macaca mulatta). J Neuroendocrinol 2000;12:167–176.
40.
Wagner CK: The many faces of progesterone: a role in adult and developing male brain. Front Neuroendocrinol 2006;27:340–359.
41.
Kalra PS, Kalra SP: Circadian periodicities of serum androgens, progesterone, gonadotropins and luteinizing hormone-releasing hormone in male rats: the effects of hypothalamic deafferentation, castration and adrenalectomy, Endocrinology 1977;101:1821–1827.
42.
Phelps SM, Lydon JP, O’Malley BW, Crews D: Regulation of male sexual behavior by progesterone receptor, sexual experience, and androgen. Horm Behav 1998;34:294–302.
43.
Tillet Y, Caldani M, Batailler M: Anatomical relationships of monoaminergic and neuropeptide Y-containing fibres with luteinizing hormone-releasing hormone systems in the preoptic area of the sheep brain: immunohistochemical studies. J Chem Neuroanat 1989;2:319–326.
44.
Chen WP, Witkin JW, Silverman AJ: Gonadotropin releasing hormone (GnRH) neurons are directly innervated by catecholamine terminals. Synapse 1989;3:288–290.
45.
Arendash GW, Gallo RV: Serotonin involvement in the inhibition of episodic luteinizing hormone release during electrical stimulation of the midbrain dorsal raphe nucleus in ovariectomized rats. Endocrinology 1978;102:1199–1206.
46.
Wada K, Hu L, Mores N, Navarro CE, Fuda H, Krsmanovic LZ, Catt KJ: Serotonin (5-HT) receptor subtypes mediate specific modes of 5-HT-induced signaling and regulation of neurosecretion in gonadotropin-releasing hormone neurons. Mol Endocrinol 2006;20:125–135.
47.
Clemens JA, Tinsley FC, Fuller RW: Evidence for a dopaminergic component in the series of neural events that lead to the pro-oestrous surge of LH. Acta Endocrinol (Copenh) 1977;85:18–24.
48.
Yoshida H, Paruthiyil S, Butler P, Weiner RI: Role of cAMP signaling in the mediation of dopamine-induced stimulation of GnRH secretion via D1 dopamine receptors in GT1-7 cells. Neuroendocrinology 2004;80:2–10.
49.
De La Garza R 2nd, Fabrizio KR, Gupta A: Relevance of rodent models of intravenous MDMA self-administration to human MDMA consumption patterns. Psychopharmacology (Berl) 2007;189:425–434.
50.
Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Ullrich T, Rice KC, Woods JH: Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine (‘ecstasy’) and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl) 2003;166:202–211.
51.
Trigo JM, Panayi F, Soria G, Maldonado R, Robledo P: A reliable model of intravenous MDMA self-administration in naïve mice. Psychopharmacology (Berl) 2006;184:212–220.
52.
Beardsley PM, Balster RL, Harris LS: Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. Drug Alcohol Depend 1986;18:149–157.
53.
Lamb RJ, Griffiths RR: Self-injection of 3,4-methylenedioxymethamphetamine (MDMA) in the baboon. Psychopharmacology (Berl) 1987;91:268–272.
54.
Lile JA, Ross JT, Nader MA: A comparison of the reinforcing efficacy of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) with cocaine in rhesus monkeys. Drug Alcohol Depend 2005;78:135–140.
55.
Ratzenboeck E, Saria A, Kriechbaum N, Zernig G: Reinforcing effects of MDMA (‘ecstasy’) in drug-naïve and cocaine-trained rats. Pharmacology 2001;62:138–144.
56.
Gagnaire F, Micillino JC: Effects of triadimefon on extracellular dopamine, DOPAC, HVA and 5-HIAA in adult rat striatum. Toxicology 2006;217:91–104.
57.
Caudle WM, Richardson JR, Wang M, Miller GW: Perinatal heptachlor exposure increases expression of presynaptic dopaminergic markers in mouse striatum. Neurotoxicology 2005;26:721–728.
58.
Khan IA, Thomas P: Aroclor 1254 inhibits tryptophan hydroxylase activity in rat brain. Arch Toxicol 2004;78:316–320.
59.
Khan IA, Thomas P: PCB congener-specific disruption of reproductive neuroendocrine function in Atlantic croaker. Mar Environ Res 2006;62(suppl):s25–s28.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.